Thus, agonistic TRAIL-R1 specific antibodies or TRAIL-R1 targeting variants of TRAIL were regarded as having a higher therapeutic potential than normal TRAIL in the treatment of pancreatic carcinoma. This evidence concerns the gene TNFSF10 and exocrine pancreatic carcinoma.